Abstract
Background and Aims : FCS is a rare autosomal recessive disorder of impaired lipoprotein lipase (LPL) function, elevated TG levels, abdominal pain and pancreatitis. Current treatment (extremely low-fat diet <10% fat/day to reduce TG levels ≤750mgldL) is ineffective. Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor that reduces circulating levels of TGs.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
